 Viventia Biotech Inc. today announced that it has received clearance from Health Canada to initiate a Phase II study evaluating Proxinium™ for the treatment of patients with chemotherapy-refractory recurrent head and neck cancer. “This clearance will allow us to expand our proposed Phase II trial for Proxinium™ to include Canadian patients and reflects our strategy to ultimately develop Proxinium™ on a global basis,” said Dr. Nick Glover, Viventia’s President and CEO.
Continue reading…
|
